Stock News

Fishman Jay A LTD Has Cut Its Pfizer (PFE) Position by $870,905; As Chevron New (CVX) Shares Declined, Hyman Charles D Has Cut Holding by $333,333

Fishman Jay A Ltd decreased its stake in Pfizer Inc (PFE) by 3.39% based on its latest 2017Q3 regulatory filing with the SEC. Fishman Jay A Ltd sold 24,883 shares as the company’s stock declined 3.45% while stock markets rallied. The institutional investor held 709,510 shares of the health care company at the end of 2017Q3, valued at $25.33 million, down from 734,393 at the end of the previous reported quarter. Fishman Jay A Ltd who had been investing in Pfizer Inc for a number of months, seems to be less bullish one the $220.19B market cap company. The stock decreased 0.14% or $0.05 during the last trading session, reaching $36.94. About 29.54M shares traded or 85.47% up from the average. Pfizer Inc. (NYSE:PFE) has declined 2.76% since January 20, 2017 and is downtrending. It has underperformed by 19.46% the S&P500.

Hyman Charles D decreased its stake in Chevron Corp New (CVX) by 3.23% based on its latest 2017Q3 regulatory filing with the SEC. Hyman Charles D sold 2,849 shares as the company’s stock declined 3.45% while stock markets rallied. The institutional investor held 85,325 shares of the integrated oil company at the end of 2017Q3, valued at $10.03M, down from 88,174 at the end of the previous reported quarter. Hyman Charles D who had been investing in Chevron Corp New for a number of months, seems to be less bullish one the $249.39B market cap company. The stock decreased 0.22% or $0.29 during the last trading session, reaching $131.3. About 6.05M shares traded or 11.74% up from the average. Chevron Corporation (NYSE:CVX) has risen 6.68% since January 20, 2017 and is uptrending. It has underperformed by 10.02% the S&P500.

Investors sentiment increased to 0.96 in 2017 Q3. Its up 0.02, from 0.94 in 2017Q2. It is positive, as 53 investors sold PFE shares while 700 reduced holdings. 106 funds opened positions while 620 raised stakes. 4.06 billion shares or 0.86% more from 4.02 billion shares in 2017Q2 were reported. Ameriprise Fin Incorporated holds 1.02% or 59.84M shares. Manchester Cap Limited Liability Corp has invested 0.16% of its portfolio in Pfizer Inc. (NYSE:PFE). 26,360 are held by Captrust Fincl. Van Cleef Asset Managementinc reported 92,410 shares. Hanson Mcclain accumulated 13,525 shares or 0.04% of the stock. Peoples Svcs Corp holds 119,680 shares or 2.42% of its portfolio. Bollard Gru Ltd stated it has 0.15% of its portfolio in Pfizer Inc. (NYSE:PFE). Hilltop Hldgs Inc holds 0.69% or 64,261 shares in its portfolio. Creative Planning, Kansas-based fund reported 745,352 shares. Smith Chas P Associates Pa Cpas reported 647,127 shares. 4,994 were reported by Cranbrook Wealth Management Ltd Llc. Dnb Asset Mngmt As owns 617,901 shares. Gulf International Bancorporation (Uk) Limited holds 1.89M shares or 0.91% of its portfolio. New York-based Trustco Bancorp Corp N Y has invested 1.34% in Pfizer Inc. (NYSE:PFE). Kames Capital Public Limited Co reported 0.75% in Pfizer Inc. (NYSE:PFE).

Fishman Jay A Ltd, which manages about $498.38 million and $490.42M US Long portfolio, upped its stake in Titan International Inc (NYSE:TWI) by 70,030 shares to 2.90 million shares, valued at $29.47 million in 2017Q3, according to the filing. It also increased its holding in Alphabet Inc. A by 1,942 shares in the quarter, for a total of 27,016 shares, and has risen its stake in Amazon.Com Inc (NASDAQ:AMZN).

Analysts await Pfizer Inc. (NYSE:PFE) to report earnings on January, 30. They expect $0.56 EPS, up 19.15% or $0.09 from last year’s $0.47 per share. PFE’s profit will be $3.34 billion for 16.49 P/E if the $0.56 EPS becomes a reality. After $0.67 actual EPS reported by Pfizer Inc. for the previous quarter, Wall Street now forecasts -16.42% negative EPS growth.

Since August 4, 2017, it had 0 insider buys, and 10 selling transactions for $16.36 million activity. READ IAN C also sold $6.70M worth of Pfizer Inc. (NYSE:PFE) shares. 6,750 shares were sold by MACKENZIE ALEXANDER R, worth $249,750 on Friday, December 15. $296,560 worth of Pfizer Inc. (NYSE:PFE) shares were sold by JOHNSON RADY A. SUSMAN SALLY also sold $1.34M worth of Pfizer Inc. (NYSE:PFE) shares. The insider DAMELIO FRANK A sold $3.21 million.

Among 21 analysts covering Pfizer (NYSE:PFE), 9 have Buy rating, 1 Sell and 11 Hold. Therefore 43% are positive. Pfizer had 68 analyst reports since July 29, 2015 according to SRatingsIntel. Piper Jaffray maintained it with “Overweight” rating and $48 target in Friday, August 28 report. The stock has “Buy” rating by BMO Capital Markets on Tuesday, September 5. Argus Research maintained the shares of PFE in report on Wednesday, July 29 with “Buy” rating. The rating was maintained by BMO Capital Markets on Tuesday, August 1 with “Hold”. The rating was maintained by BMO Capital Markets on Monday, June 12 with “Hold”. Jefferies maintained Pfizer Inc. (NYSE:PFE) rating on Tuesday, January 16. Jefferies has “Hold” rating and $40.0 target. S&P Research maintained Pfizer Inc. (NYSE:PFE) on Wednesday, October 28 with “Hold” rating. The firm has “Neutral” rating given on Wednesday, November 25 by SunTrust. The stock has “Buy” rating by Piper Jaffray on Wednesday, August 2. On Thursday, May 12 the stock rating was initiated by Berenberg with “Hold”.

Among 34 analysts covering Chevron Corporation (NYSE:CVX), 21 have Buy rating, 1 Sell and 12 Hold. Therefore 62% are positive. Chevron Corporation had 102 analyst reports since August 4, 2015 according to SRatingsIntel. On Tuesday, October 24 the stock rating was maintained by Cowen & Co with “Buy”. The stock of Chevron Corporation (NYSE:CVX) has “Overweight” rating given on Wednesday, October 18 by Morgan Stanley. Argus Research upgraded it to “Buy” rating and $100 target in Wednesday, December 16 report. The rating was maintained by Credit Suisse with “Buy” on Wednesday, August 23. The company was upgraded on Wednesday, March 9 by Wolfe Research. The stock of Chevron Corporation (NYSE:CVX) has “Buy” rating given on Thursday, August 24 by Piper Jaffray. Barclays Capital maintained Chevron Corporation (NYSE:CVX) on Monday, October 12 with “Equal-Weight” rating. Macquarie Research downgraded the shares of CVX in report on Wednesday, June 21 to “Neutral” rating. As per Wednesday, December 20, the company rating was maintained by RBC Capital Markets. Goldman Sachs upgraded the shares of CVX in report on Monday, October 31 to “Buy” rating.

Since August 1, 2017, it had 0 buys, and 4 sales for $11.07 million activity. JOHNSON JAMES WILLIAM had sold 31,000 shares worth $3.43 million on Tuesday, August 1. On Wednesday, August 2 the insider Yarrington Patricia E sold $4.33M. The insider Pate R. Hewitt sold $3.06 million.

Investors sentiment decreased to 0.95 in Q3 2017. Its down 0.08, from 1.03 in 2017Q2. It fall, as 43 investors sold CVX shares while 696 reduced holdings. 121 funds opened positions while 584 raised stakes. 1.18 billion shares or 1.43% more from 1.16 billion shares in 2017Q2 were reported. Nexus Mgmt Inc owns 10,300 shares for 0.19% of their portfolio. Staley Cap Advisers Inc stated it has 269,997 shares. Moors Cabot invested in 1.25% or 73,341 shares. Pettyjohn Wood & White invested 1.8% in Chevron Corporation (NYSE:CVX). Ntv Asset Mngmt Ltd Limited Liability Company reported 0.86% stake. Dearborn Prns Ltd Liability Corporation has invested 2.37% in Chevron Corporation (NYSE:CVX). Budros Ruhlin And Roe stated it has 2,313 shares. Canal Insur Co stated it has 69,240 shares or 2.84% of all its holdings. Pnc Financial Serv Grp Inc Inc accumulated 4.79M shares. American Natl Ins Tx holds 154,795 shares or 0.96% of its portfolio. 7,753 are owned by Nichols & Pratt Advisers Ltd Liability Partnership Ma. Sonata Cap, Washington-based fund reported 8,350 shares. Azimuth Capital Management Ltd Limited Liability Company holds 129,835 shares. Cap Wealth Planning Lc stated it has 21,823 shares. Fil Ltd invested in 0.45% or 1.33M shares.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.


Leave a Reply

Your email address will not be published. Required fields are marked *